Classical Hodgkin lymphoma with reduced β2M/MHC class i expression is associated with inferior outcome independent of 9p24.1 status

Cancer Immunology Research

Volumn 4, Issue 11, 2016, Pages 910-916

  Roemer, Margaretha G M ^a,b   Advani, Ranjana H ^c   Redd, Robert A ^a   Pinkus, Geraldine S ^d   Natkunam, Yasodha ^c   Ligon, Azra H ^d   Connelly, Courtney F ^a   Pak, Christine J ^a   Carey, Christopher D ^d   Daadi, Sarah E ^c   Chapuy, Bjoern ^a   De Jong, Daphne ^b   Hoppe, Richard T ^c   Neuberg, Donna S ^a   Shipp, Margaret A ^a   Rodig, Scott J ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; CD274 PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; PDCD1LG2 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANTIGEN PRESENTATION; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; ADOLESCENT; CHROMOSOME 9; CHROMOSOME ABERRATION; GENE EXPRESSION; GENETICS; HODGKIN DISEASE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGEN PRESENTATION; B7-H1 ANTIGEN; BETA 2-MICROGLOBULIN; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; YOUNG ADULT;

EID: 85016164544     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0201     Document Type: Article

References (22)

1. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
2. Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015;125: 1061-72.
3. Steidl C, Shah SP, Woolcock BW, Rui L, KawaharaM, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471:377-81.
4. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA,Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol 2016;34:2690-7.
5. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
6. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016 Jun 27. [Epub ahead of print].
7. Younes A, Santoro A, Shipp MA, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study. Lancet Oncol 2016;17:1283-94.
8. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 2016;127:869-81.
9. Diepstra A, NiensM, Vellenga E, van Imhoff GW, Nolte IM, Schaapveld M, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 2005;365:2216-24.
10. Lee SP, Constandinou CM, Thomas WA, Croom-Carter D, Blake NW, Murray PG, et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition. Blood 1998;92:1020-30.
11. Oudejans JJ, Jiwa NM, Kummer JA, Horstman A, Vos W, Baak JP, et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and-negative Hodgkin's disease. Blood 1996;87:3844-51.
12. Huang X, Kushekhar K, Nolte I, Kooistra W, Visser L, Bouwman I, et al. HLA associations in classicalHodgkin lymphoma: EBV statusmatters. PLoS One 2012;7:e39986.
13. Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, teMeerman GJ, Niens M, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007;25:3101-8.
14. Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep 2015;13:1418-31.
15. Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A 2016;113:5999-6004.
16. de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010;16:1272-80.
17. 8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14:2028-35.
18. Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 2010;59:926-33.
19. Turcotte S, Katz SC, Shia J, Jarnagin WR, Kingham TP, Allen PJ, et al. Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases. Cancer Immunol Res 2014;2:530-7.
20. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
21. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100-8.
22. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819-29.